Publication date: Available online 15 February 2019
Source: Journal of Allergy and Clinical Immunology
Author(s): Kanokvalai Kulthanan, Saowalak Hunnangkul, Papapit Tuchinda, Leena Chularojanamontri, Puncharas Weerasubpong, Chanika Subchookul, Marcus Maurer
Abstract
Background
Several treatment options for cold urticaria (ColdU) have been studied and reported, but systematic reviews and meta-analyses are limited.
Objectives
To meta-analyze and review the efficacy and safety of ColdU treatments.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Suitable reports were identified by searching PubMed, Scopus, and Web of Science. Our systematic review included 16 studies, 9 of which met the eligibility criteria for the meta-analysis. We analyzed the effects of treatments on the critical temperature thresholds (CTTs) and critical stimulation time thresholds (CSTTs), as well as on the rates of complete response and adverse events.
Results
Our pooled meta-analyses showed that non-sedating, second-generation H1-antihistamines (nsAHs) are effective in the treatment of ColdU, and that the updosing of nsAHs significantly reduced CTTs relative to their own standard doses and placebos. In 4 studies involving CSTT, the updosing of nsAHs also showed significantly better CSTTs than their own standard doses or placebos. Omalizumab resulted in a marked reduction of CTTs in H1-AH-resistant patients. Of 118 adverse events in 8 studies, standard-dose nsAHs, updosed nsAHs, and omalizumab produced lower numbers of adverse events than first-generation AHs.
Conclusions
Our study showed that higher dosages of nsAHs were more effective than their own standard dosages in controlling ColdU symptoms. Increasing the dosages was not significantly associated with higher adverse event rates. Omalizumab at 150 and 300 mg every 4 weeks was shown to be effective for ColdU patients refractory to AHs.
http://bit.ly/2GuJZQd
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου